The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis

References

• Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–1348. doi:10.1001/jama.2017.2719.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–322. doi:10.1001/jamaoto.2014.1.
   PubMed Web of Science ®Google Scholar
• Riesco-Eizaguirre G, Santisteban P. Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome. Eur J Endocrinol. 2016;175(5):R203–17. doi:10.1530/EJE-16-0202.
   PubMed Web of Science ®Google Scholar
• Vuong HG, Altibi AM, Abdelhamid AH, Ngoc PU, Quan VD, Tantawi MY, Elfil M, Vu TL, Elgebaly A, Oishi N, et al. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review. Oncotarget. 2017;8(6):10637–10649. doi:10.18632/oncotarget.v8i6.
   PubMedGoogle Scholar
• Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, et al. Genetic alterations and their clinical implications in high-recurrence risk papillary thyroid cancer. Cancer Res Treat. 2017;49(4):906–914. doi:10.4143/crt.2016.424.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866. doi:10.1038/nrc1997.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838. doi:10.1038/nature03702.
   PubMed Web of Science ®Google Scholar
• Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;18(5):54.
   Google Scholar
• Detassis S, Grasso M, Del Vescovo V, Denti MA. microRNAs make the call in cancer personalized medicine. Front Cell Dev Biol. 2017;22(5):86. doi:10.3389/fcell.2017.00086.
   Google Scholar
• Stokowy T, Gawel D, Wojtas B. Differences in miRNA and mRNA profile of papillary thyroid cancer variants. Int J Endocrinol. 2016;2016:1427042. doi:10.1155/2016/1427042.
   PubMedGoogle Scholar
• Tang J, Kong D, Cui Q, Wang K, Zhang D, Yuan Q, Liao X, Gong Y, Wu G. Bioinformatic analysis and identification of potential prognostic microRNAs and mRNAs in thyroid cancer. PeerJ. 2018;4(6):e4674. doi:10.7717/peerj.4674.
   Google Scholar
• Chapelle AD, Jazdzewski K. MicroRNAs in Thyroid Cancer. J Clin Endocrinol Metab. 2011;96(11):3326–3336. doi:10.1210/jc.2011-1004.
   PubMed Web of Science ®Google Scholar
• Chou CK, Liu RT, Kang HY. MicroRNA-146b: A novel biomarker and therapeutic target for human papillary thyroid cancer. Int J Mol Sci. 2017 15;18(3):E636. doi:10.3390/ijms18030636.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao C, Wang C, Liu J, Li X, Dong M, et al. MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer. J Cancer. 2017 30;8(9):1704–1716. doi:10.7150/jca.16961.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi C, Zhou X, Bian X, Ping Y, et al. miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas. Oncotarget. 2015;6(30):29129–29142. doi:10.18632/oncotarget.4895.
   PubMedGoogle Scholar
• Ramírez-Moya J, Wert-Lamas L, Santisteban P. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene. 2018;37:3369–3383. doi:10.1038/s41388-017-0088-9.
   PubMed Web of Science ®Google Scholar
• Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC, Liu RT. MiR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the brafv600e mutation. Thyroid. 2010;20:489–494. doi:10.1089/thy.2009.0027.
   PubMed Web of Science ®Google Scholar
• Lima CR, Geraldo MV, Fuziwara CS, Kimura ET, Santos MF. MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells. BMC Cancer. 2016;16(16):108. doi:10.1186/s12885-016-2146-z.
   PubMedGoogle Scholar
• Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY, Liu RT. Prognostic Implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98:E196–205. doi:10.1210/jc.2012-2666.
   PubMed Web of Science ®Google Scholar
• Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X, Fan Y. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem. 2015;35;71–82. DOI:10.1111/j.1365-2141.1975.tb00536.x.
   Google Scholar
• Chou CK, Chi SY, Huang CH, Chou FF, Huang CC, Liu RT, Kang HY. IRAK1, a target of miR-146b, reduces cell aggressiveness of human papillary thyroid carcinoma. J Clin Endocrinol Metab. 2016;101:4357–4366. doi:10.1210/jc.2016-2276.
   PubMed Web of Science ®Google Scholar
• Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR-146b-5p regulates signal transduction of TGF-Β by repressing SMAD4 in thyroid cancer. Oncogene. 2012 12;31(15):1910–1922. doi:10.1038/onc.2011.381.
   PubMed Web of Science ®Google Scholar
• Jahanbani I, Al-Abdallah A, Ali RH, Al-Brahim N, Mojiminiyi O. Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Thyroid. 2018;28(3):319–327. doi:10.1089/thy.2017.0127.
   PubMed Web of Science ®Google Scholar
• Madsen KL, Tavernini MM, Yachimec C, Mendrick DL, Alfonso PJ, Buergin M, Olsen HS, Antonaccio MJ, Thomson AB, Fedorak RN. Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine. Am J Physiol. 1998;274(1 Pt 1):G96–102. doi:10.1152/ajpgi.1998.274.1.G96.
   PubMedGoogle Scholar
• Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL, Wagner GF. Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA. 1996;93:1792–1796. doi:10.1073/pnas.93.5.1792.
   PubMed Web of Science ®Google Scholar
• Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, et al. Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol. 2000;156:1887–1900. doi:10.1016/S0002-9440(10)65062-6.
   PubMed Web of Science ®Google Scholar
• Kanellis J, Bick R, Garcia G, Truong L, Tsao CC, Etemadmoghadam D, Poindexter B, Feng L, Johnson RJ, Sheikh-Hamad D. Stanniocalcin-1, an inhibitor of macrophage chemotaxis and chemokinesis. Am J Physiol Renal Physiol. 2003;286:F356–F362. doi:10.1152/ajprenal.00138.2003.
   PubMed Web of Science ®Google Scholar
• McCudden CR, James KA, Hasilo C, Wagner GF. Characterization of mammalian stanniocalcin receptors: mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Biol Chem. 2002;277:45249–45258. doi:10.1074/jbc.M205954200.
   PubMed Web of Science ®Google Scholar
• Chang ACM, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer. 2003;10:359–373. doi:10.1677/erc.0.0100359.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Sugita Y, Nakamori S, Miyamoto A, Shiozaki K, Nagano H, Sakon M, Monden M. Assessment of stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol. 2000;16:799–804. doi:10.3892/ijo.16.4.799.
   PubMed Web of Science ®Google Scholar
• Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001;93:1337–1343. doi:10.1093/jnci/93.17.1337.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Chang AC, Reddel RR. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene. 2009;28:1982–1992. doi:10.1038/onc.2009.65.
   PubMed Web of Science ®Google Scholar
• Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA. 2002;99:7560–7565. doi:10.1073/pnas.062181799.
   PubMed Web of Science ®Google Scholar
• Lai KP, Law AY, Yeung HY, Lee LS, Wagner GF, Wong CK. Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem Biophys Res Commun. 2007;356:968–975. doi:10.1016/j.bbrc.2007.03.074.
   PubMed Web of Science ®Google Scholar
• Hayase S, Sasaki Y, Matsubara T, Seo D, Miyakoshi M, Murata T, Ozaki T, Kakudo K, Kumamoto K, Ylaya K, et al. Expression of Stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid. 2015;25(4):425–436. doi:10.1089/thy.2014.0464.
   PubMed Web of Science ®Google Scholar
• Zeke A, Misheva M, Reményi A, Bogoyevitch MA. JNK signaling: regulation and functions based on complex protein-protein partnerships. MMBR. 2016;8(3):793–835.
   Google Scholar
• Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000 5;288(5467):870–874. doi:10.1126/science.288.5467.870.
   PubMed Web of Science ®Google Scholar
• Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. Independent regulation of JNK p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci USA. 1996 12;93(23):12908–12913. doi:10.1073/pnas.93.23.12908.
   PubMed Web of Science ®Google Scholar
• Zhou R, O’Hara SP, Chen XM. MicroRNA regulation of innate immune responses in epithelial cells. Cell Mol Immunol. 2011;8(5):371–379. doi:10.1038/cmi.2011.19.
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006 15;103(33):12481–12486. doi:10.1073/pnas.0605298103.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. Micro-RNA-146a feedback inhibits RIG-1-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol. 2009;183:2150–2158. doi:10.4049/jimmunol.0900707.
   PubMed Web of Science ®Google Scholar
• Xie YF, Shu R, Jiang SY, Song ZC, Guo QM, Dong JC, Lin ZK. miRNA-146 negatively regulates the production of pro-inflammatory cytokines via NF-κB signalling in human gingival fibroblasts. J Inflamm (Lond). 2014 6;11(1):38. doi:10.1186/s12950-014-0038-z.
   PubMedGoogle Scholar
• Dhanasekaran DN, Reddy EP. JNK-signaling: A multiplexing hub in programmed cell death. Genes Cancer. 2017;8(9–10):682–694. doi:10.18632/genesandcancer.155.
   PubMedGoogle Scholar
• Liu J, Lin A. Role of JNK activation in apoptosis: A double-edged sword. Cell Res. 2005;15(1):36–42. doi:10.1038/sj.cr.7290262.
   PubMed Web of Science ®Google Scholar
• Papa S, Bubici C. Linking apoptosis to cancer metabolism: another missing piece of JuNK. Mol Cell Oncol. 2016;3:e1103398. doi:10.1080/23723556.2015.1103398.
   PubMed Web of Science ®Google Scholar
• Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, Del Rio A, D’Santos C, Williams R, Chokshi S, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015;6:7882. doi:10.1038/ncomms8882.
   PubMed Web of Science ®Google Scholar
• Han J, Jeon M, Shin I, Kim S. Elevated STC-1 augments the invasiveness of triple-negative breast cancer cells through activation of the JNK/c-Jun signaling pathway. Oncol Rep. 2016;36(3):1764–1771. doi:10.3892/or.2016.4977.
   PubMed Web of Science ®Google Scholar
• Chan KK, Leung CO, Wong CC, Ho DW, Chok KS, Lai CL, Ng IO, Lo RC, Stanniocalcin S. 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Lett. 2017;10(403):330–338. doi:10.1016/j.canlet.2017.06.034.
   Google Scholar
• Leung C, Wong C. Effects of STC1 overexpression on tumorigenicity and metabolism of hepatocellular carcinoma. Oncotarget. 2018;9(6):6852–6861. doi:10.18632/oncotarget.v9i6.
   PubMedGoogle Scholar
• Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–1187. doi:10.1016/j.cell.2012.02.005.
   PubMed Web of Science ®Google Scholar
• Byrd AE, Brewer JW. Micro(RNA) managing endoplasmic reticulum stress. IUBMB Life. 2013;65(5):373–381. doi:10.1002/iub.v65.5.
   PubMed Web of Science ®Google Scholar
• Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell. 2010;40(2):205–215. doi:10.1016/j.molcel.2010.09.027.
   PubMed Web of Science ®Google Scholar
• Maurel M, Chevet E. Endoplasmic reticulum stress signaling: the microRNA connection. Am J Physiol Cell Physiol. 2013;304:C1117–C1126. doi:10.1152/ajpcell.00061.2013.
   PubMed Web of Science ®Google Scholar
• Emde A, Hornstein E. miRNAs at the interface of cellular stress and disease. Embo J. 2014 1;33(13):1428–1437. doi:10.15252/embj.201488142.
   PubMed Web of Science ®Google Scholar
• Lam AK. Pathology of endocrine tumors update: World Health Organization new classification 2017—other thyroid tumors. AJSP Rev Rep. 2017;22(4):209–216.
   Web of Science ®Google Scholar
• Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma. JAMA Oncol. 2016;2:1023–1029. doi:10.1001/jamaoncol.2016.0386.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–1108. doi:10.1038/nprot.2008.73.
   PubMed Web of Science ®Google Scholar